Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan. Okada M, et al. Among authors: yamazaki h. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1. doi: 10.1016/j.clml.2018.03.004. Epub 2018 Mar 15. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29610029 Free article. Clinical Trial.
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.
Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T; Japan Adult Leukemia Study Group. Ohnishi K, et al. Among authors: yamazaki h. Cancer Sci. 2012 Jun;103(6):1071-8. doi: 10.1111/j.1349-7006.2012.02253.x. Epub 2012 Apr 16. Cancer Sci. 2012. PMID: 22364419 Free PMC article. Clinical Trial.
Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia.
Takami A, Ohtake S, Morishita E, Terasaki Y, Fukushima T, Kurokawa T, Sugimori N, Matano S, Ohata K, Saito C, Yamaguchi M, Hosokawa K, Yamazaki H, Kondo Y, Nakao S. Takami A, et al. Among authors: yamazaki h. Int J Hematol. 2012 Sep;96(3):357-63. doi: 10.1007/s12185-012-1155-1. Epub 2012 Aug 15. Int J Hematol. 2012. PMID: 22893108
Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
Mori T, Koh H, Onishi Y, Kako S, Onizuka M, Kanamori H, Ozawa Y, Kato C, Iida H, Suzuki R, Ichinohe T, Kanda Y, Maeda T, Nakao S, Yamazaki H. Mori T, et al. Among authors: yamazaki h. Int J Hematol. 2016 Apr;103(4):461-8. doi: 10.1007/s12185-016-1960-z. Epub 2016 Feb 24. Int J Hematol. 2016. PMID: 26910242
Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.
Onishi Y, Mori T, Kako S, Koh H, Uchida N, Kondo T, Kobayashi T, Yabe H, Miyamoto T, Kato K, Suzuki R, Nakao S, Yamazaki H; Adult Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Onishi Y, et al. Among authors: yamazaki h. Biol Blood Marrow Transplant. 2017 Dec;23(12):2137-2142. doi: 10.1016/j.bbmt.2017.08.020. Epub 2017 Aug 24. Biol Blood Marrow Transplant. 2017. PMID: 28844947 Free article.
Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Yamazaki H, Ohta K, Iida H, Imada K, Obara N, Tokumine Y, Tomiyama Y, Usuki K, Imajo K, Miyamura K, Sasaki O, Fanghong Z, Hattori T, Tajima T, Matsuda A, Nakao S. Yamazaki H, et al. Int J Hematol. 2019 Aug;110(2):187-196. doi: 10.1007/s12185-019-02683-1. Epub 2019 Jun 10. Int J Hematol. 2019. PMID: 31183813 Clinical Trial.
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y. Nagafuji K, et al. Among authors: yamazaki h. Int J Hematol. 2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. Epub 2019 Sep 19. Int J Hematol. 2019. PMID: 31538327 Clinical Trial.
Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation.
Hiramoto N, Yamazaki H, Nakamura Y, Uchida N, Murata M, Kondo T, Yoshioka S, Eto T, Nishikawa A, Kimura T, Ichinohe T, Atsuta Y, Onishi Y, Suzuki R, Mori T; Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation. Hiramoto N, et al. Among authors: yamazaki h. Ann Hematol. 2022 Jan;101(1):165-175. doi: 10.1007/s00277-021-04664-z. Epub 2021 Sep 21. Ann Hematol. 2022. PMID: 34546409
3,121 results